As of close of business last night, Healthequity Inc’s stock clocked out at $79.48, up 0.13% from its previous closing price of $79.38. In other words, the price has increased by $+0.10 from its previous closing price. On the day, 645309 shares were traded.
Ratios:
To gain a deeper understanding of HQY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.40. For the most recent quarter (mrq), Quick Ratio is recorded 4.76 and its Current Ratio is at 4.76. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.45.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on January 03, 2024, initiated with a Overweight rating and assigned the stock a target price of $84.
On September 21, 2023, Robert W. Baird Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $79 to $87.
Goldman Upgraded its Sell to Neutral on October 21, 2022, whereas the target price for the stock was revised from $64 to $77.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 22 ’24 when Kessler Jon sold 33,765 shares for $79.81 per share. The transaction valued at 2,694,731 led to the insider holds 126,635 shares of the business.
Ladd Delano sold 2,558 shares of HQY for $211,265 on Mar 01 ’24. The EVP, GC & CORPORATE SECRETARY now owns 47,438 shares after completing the transaction at $82.59 per share. On Feb 09 ’24, another insider, Ladd Delano, who serves as the EVP, GC & CORPORATE SECRETARY of the company, sold 2,499 shares for $80.00 each. As a result, the insider received 199,920 and left with 49,996 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HQY now has a Market Capitalization of 6.85B and an Enterprise Value of 7.38B. As of this moment, Healthequity’s Price-to-Earnings (P/E) ratio for their current fiscal year is 124.19, and their Forward P/E ratio for the next fiscal year is 22.21. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.85 while its Price-to-Book (P/B) ratio in mrq is 3.36. Its current Enterprise Value per Revenue stands at 7.38 whereas that against EBITDA is 26.01.
Stock Price History:
The Beta on a monthly basis for HQY is 0.53, which has changed by 36.31% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, HQY has reached a high of $84.49, while it has fallen to a 52-week low of $48.86. The 50-Day Moving Average of the stock is 79.46, while the 200-Day Moving Average is calculated to be 70.82.
Shares Statistics:
It appears that HQY traded 601.84K shares on average per day over the past three months and 666.13k shares per day over the past ten days. A total of 86.13M shares are outstanding, with a floating share count of 84.15M. Insiders hold about 2.33% of the company’s shares, while institutions hold 99.91% stake in the company. Shares short for HQY as of Feb 29, 2024 were 2.97M with a Short Ratio of 4.94, compared to 3.19M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.46% and a Short% of Float of 4.03%.
Earnings Estimates
As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.66 for the current quarter, with a high estimate of $0.74 and a low estimate of $0.63, while EPS last year was $0.5. The consensus estimate for the next quarter is $0.67, with high estimates of $0.72 and low estimates of $0.61.
Analysts are recommending an EPS of between $2.99 and $2.74 for the fiscal current year, implying an average EPS of $2.87. EPS for the following year is $3.57, with 10 analysts recommending between $3.79 and $3.38.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for HQY’s current fiscal year. The highest revenue estimate was $1.16B, while the lowest revenue estimate was $1.15B, resulting in an average revenue estimate of $1.15B. In the same quarter a year ago, actual revenue was $999.59M, up 15.50% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $1.31B in the next fiscal year. The high estimate is $1.37B and the low estimate is $1.27B. The average revenue growth estimate for next year is up 13.50% from the average revenue estimate for this year.
